Print

BDS organises 2-day EDC training

2017-07-17

BioDetection Systems organises together with CAAT, TNO, JRC, Biopredic, BASF and DTU a 2-day training for:

Quantitive Human Cell & Effect Based In Vitro Bioanalysis for Assessing Endocrine Disrupting Compound (EDCs)

on 7th-8th September 2017 on the Science Park in Amsterdam

You will learn in a 2 day extensive hands-on training how you can use a panel of standardized stable human- and yeast reporter cell lines for rapid screening of hazards of pure chemicals and complex mixtures on multiple adverse outcome pathways. This includes those pathways prioritized in the current regulatory context of EDC assessment, including interference with estrogen-, androgen-, and thyroid hormone signaling. This will include assessment of metabolic conversions (S9, metabolically competent liver cells) of EDCs using various approaches and assessment of their effects on steroidogenesis.

You will learn more about modern robotic and automated high-through-put screening using down-scaled 96-wells to 384-wells formats. The chemical activated luciferase (CALUX) assays are available for testing of relevant matrices such as food, blood, urine, mother milk and many different environmental matrices.

All steps needed from extraction, clean-up, cell culture handling, luminometer analysis and calculations of effect concentrations and toxic equivalents will be presented in state of the art manner following current guidelines (e.g. ISO 17025, OECD TG455-like, ISO 19040-3).

You will learn to use these data in the context of chemical risk assessment, including in silico modeling, metabolism of compounds, database use and comparative data analysis and read-across, and also linkage to so-called adverse outcome pathways.

Additionally in several oral presentations the current applications in chemicals, mixture toxicity, food, environmental and public health testing are presented.

 

documents

BDS proud partner of EU project AquaNES

2017-01-06

AquaNES intends to catalyze innovations in water and waste water treatment processes and management through improved combinations of natural and engineered components. The project focuses on 13 demonstration sites in Europe, India and Israel covering a representative range of regional, climatic, and hydro geological conditions. Among the demonstrated solutions are natural treatment processes such as bank filtration (BF), managed aquifer recharge (MAR) and constructed wetlands (CW) plus engineered pre- and post-treatment options.

The AquaNES consortium (see partnersassembles at partnership of (waste)water utilities,  SMEs and industries as well as high level academic partners and research institutes from seven European countries, Israel and India, representing a good balance along a technology innovation value chain.

 

Our SME’s and industries provide existing and new pre- or post-treatment technologies, monitoring devices or software tools which are integrated by water utilities in combined natural and engineered treatment schemes to demonstrate and validate the treatment efficacy of the combined system. The close collaboration with partnering water utilities will speed-up the deployment of successfully operating combined treatment processes.

 

AquaNES specific objectives are

·         to demonstrate the benefits of post-treatment options such as membranes, activated carbon and ozonation after bank filtration for the production of safe drinking water

·         to validate the treatment and storage capacity of soil-aquifer systems in combination with oxidative pre-treatments

·         to demonstrate the combination of constructed wetlands with different technical post- or pre-treatment options (ozone or bioreactor systems) as a waste water treatment option

·         to evidence reductions in operating costs and energy consumption

·         to test a robust risk assessment framework for cNES

·         to deliver design guidance for cNES informed by industrial or near-industrial scale experiences

·         to identify and profile new market opportunities in Europe and overseas for cNES

 

BDS’s main involvement is in work package 4 (WP4): Risk Assessment and Water Quality Control. This work package will design and demonstrate an efficient quantitative water quality assessment framework for cNES that is easy to use and allows integration of innovative monitoring approaches. Modules will be designed using a set of monitoring systems for a variety of emerging water quality issues such as fecal contamination, antibiotic resistance genes and biological effects of complex mixtures of chemicals. The effectiveness of cNES to remove the monitored biological and chemical contamination will be demonstrated.

The specific goals of WP4 are to:

·         Design a water quality assessment framework for cNES

·         Implement innovative monitoring modules to demonstrate cNES treatment efficacy:
      - An innovative sensor to monitor fecal contamination
      - An innovative monitoring system to assess antibiotic resistance genes
      - Quantitative CALUX bioassays to monitor endocrine disrupting/toxic compounds

·         Visualization techniques and integrate results of multiple monitoring tools in an• Demonstrate data-processing and -vis open access software based water quality reporting tool

·         Demonstrate its use in selected demonstration sites from WP1-3 and derive an interactive water quality assessment 
tool to be embedded in the decision support platform in WP6.

 

BDS’s main tasks in the project are:

·         Implementation of a range of CALUX bioassays in demonstration sites.
Adaptation of monitoring technologies to needs of combined natural engineered treatment systems. Development of tailored monitoring programmes. In that frame We interact with other WPs (particularly WP6) for data exchange and –interpretation,

·         Participation in the exploitation plan development for its bioassays and dissemination activities (exhibit at fairs, contribute on conferences)

 

Visit www.aquanes.eu for more information.

 

The AquaNes Project has received funding from the Europian Union’s Horizon 2020 research innovation programme under grant agreement no. 689450

BDS coordinates the BBI project FUNGUSCHAIN

2016-12-20

FUNGUSCHAIN - 1st press release

The project, with a budget of 11 million euros, is co-funded by the Bio Based Industries Joint Undertaking (BBI JU) under the European Union’s Horizon 2020 research and innovation programme. The BBI JU is a new €3.7 billion Public-Private Partnership between the EU and the Bio-based Industries Consortium. It is an industry driven initiative aiming to boost the bio-based economy.

FUNGUSCHAIN will make use of new cascading processes to extract high value molecules from  residues from mushroom farming, following the requirements of a range of end-users. A first extraction will yield antimicrobials & antioxidants, proteins, polyols and polysaccharides. Further processing will complete the value chain for delivering cleaning, food and plastic products. The remaining residues will be used for composting or biogas synthesis, thus closing the agricultural cycle.  BDS will coordinate, but will also be involved in identifying bio-active fractions of interest and will develop and employ early stage safety evaluations of the potential end products using green chemistry approaches. 

Participants: 4 large industries (Corbion, Novamont, S.p.A, Monaghan Mushrooms Group, Saponia d. d.) 8 SMEs (BioDetection Systems BV, Biotrend SA, Biozoon GmbH, Condensia Química SA, Mi-Plast d.o.o., Neem Biotech Ltd., OWS, Tecnaro Gesellschaft zur Industriellen Anwendung Nachwachsender Rohstoffe Gmbh) and 4 research and technology development entities (AITIIP Technology Centre, European Centre for Nanostructured Polymers, University of Alicante and KTH Royal Institute of Technology).

documents

10th BioDetectors conference 2017

You are invited to attend and actively partipate (Presentation or Poster) to the 10th BioDetectors Conference 2017. The meeting will bring together scientists involved in the development and application of in vitro effect-based bioanalysis technologies.

 

 

 

2016-01-28

Partner in EU-ToxRisk

BioDetection Systems is proud to be a partner in the major (30 Million €) H2020-supported collaborative project  on toxicological risk assessment: “An Integrated European ‘Flagship’ Program Driving Mechanism-based Toxicity Testing and Risk Assessment for the 21st Century” (EU-ToxRisk). In this project  academia joins forces with small and medium-sized enterprises (SMEs), large industry, contract research organisations (CROs) and regulatory bodies to achieve a paradigm shift in toxicology towards a more efficient and animal-free chemical safety assessment. These new concepts involve cutting-edge human-relevant in vitro non-animal methods and in silico computational technologies to translate molecular mechanistic understanding of toxicity into safety testing strategies. The workflow is arranged in such a way that cost-effective in silico and in high throughput in vitro methods (such as BDS’ CALUX methods) precede more complicated methods, avoiding unnecessarily complex and costly testing procedures. From project’s start, a unique integrated strategy to exploit and disseminate the consortium tools and knowledge is in place, as described in a separate workpackage, led by BDS. For further details see www.eu-toxrisk.eu

 

2016-01-13

9th BioDetectors conference 2016

"You are invited to attend and actively participate (Presentation or Poster) to the 9th BioDetectors Conference 2016. The meeting will bring together scientists involved in the development and application of in vitro effect-based bioanalysis technologies"

documents

 


2014-12-16

BDS on Swiss TV

"The presence of endocrine disruptors in waterproofing sprays can disrupt our hormonal system. Peter Behnisch, marketing director at BioDetection Systems in Amsterdam, explains the revolutionary technology developed by his lab to test the effects of different chemicals on living cells."

http://www.rts.ch/play/tv/a-bon-entendeur/video/sprays-impermeabilisants-quels-effets-nocifs-pour-la-sante?id=6391843

 

2014-01-27

ISO 17025 Accreditation: Confirmative analysis of nondioxin-like PCBs

Dear customers,

Please let us inform you about our newly developed and now ISO 17025 accredited service laboratory analysis: 

Chemical analysis of non-dioxin-like PCBs in feed/food.

Therefore we are now able to offer you a cost-efficient all-in-3 analysis for  

  • dioxins PCDD/PCDFs + dl-PCBs (by cell based screening DR CALUX®) and 
  • non-dl-PCBs (by confirmative GC-ECD analysis) 

 …..which are demanded e.g. by the EC/252/2012 (food) and EC/278/2012 (feed).

We are looking forward to serve you with this additional chemical analysis.

 

2010-04-12

First National Monitoring Program for food and feed by DR CALUX® analysis in Chile

Since December 2008 the Ministery of Agriculture in Santiago de Chile started an intensive National Monitoring Program to evaluate the safety of several different food/feeds regarding dioxins/dioxin-like PCBs in Chile in cooperation with BDS’ local partner Labser.